{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:22:32Z","timestamp":1790353352960,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01919","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T03:11:31Z","timestamp":1565838691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Effects of Omalizumab on Fc\u03b5RI and IgE Expression in Lesional Skin of Bullous Pemphigoid"],"prefix":"10.3389","volume":"10","author":[{"given":"S. Morteza","family":"Seyed Jafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Gadaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Feldmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Yawalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Borradori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schlapbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2018.12.015","article-title":"IgE blockade in autoimmunity: omalizumab induced remission of bullous pemphigoid","volume":"198","author":"James","year":"2019","journal-title":"Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e12829","DOI":"10.1111\/dth.12829","article-title":"Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: a case report","volume":"2019","author":"Vico-Alonso","year":"2019","journal-title":"Dermatol Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e107725","DOI":"10.1371\/journal.pone.0107725","article-title":"Human eosinophils express the high affinity IgE receptor, FcepsilonRI, in bullous pemphigoid","volume":"9","author":"Messingham","year":"2014","journal-title":"PLoS ONE"},{"key":"B4","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid","volume":"120","author":"Dimson","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"A Pathogenic role for IgE in autoimmunity: bullous pemphigoid ige reproduces the early phase of lesion development in human skin grafted to nu\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clim.2012.02.003","article-title":"IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses","volume":"143","author":"Fania","year":"2012","journal-title":"Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2340\/00015555-2101","article-title":"Enzyme-linked immunoassay index for Anti-NC16a IgG and IgE autoantibodies correlates with severity and activity of bullous pemphigoid","volume":"96","author":"Kalowska","year":"2016","journal-title":"Acta Dermato Venereol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1365-2133.2011.10481.x","article-title":"Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis","volume":"165","author":"Yayli","year":"2011","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","article-title":"IgE Basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice","volume":"127","author":"Zone","year":"2007","journal-title":"J Invest Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12026-014-8547-7","article-title":"Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid","volume":"59","author":"Messingham","year":"2014","journal-title":"Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","article-title":"Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid","volume":"144","author":"Iwata","year":"2008","journal-title":"Arch Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jim.2009.04.013","article-title":"A novel ELISA reveals high frequencies of BP180\u2013specific IgE production in bullous pemphigoid","volume":"346","author":"Messingham","year":"2009","journal-title":"J Immunol Methods."},{"key":"B15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/1744666X.2016.1123092","article-title":"IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases","volume":"12","author":"van Beek","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful management of severe infant bullous pemphigoid with omalizumab","volume":"166","author":"Dufour","year":"2012","journal-title":"Br J Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.7754\/Clin.Lab.2013.130642","article-title":"Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200","volume":"60","author":"Yalcin","year":"2014","journal-title":"Clin Lab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/jdv.15350","article-title":"Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients","volume":"33","author":"Marzano","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bjd.14459","article-title":"IgE and FcepsilonRI are highly expressed on innate cells in psoriasis","volume":"175","author":"Yan","year":"2016","journal-title":"Br J Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/cea.13066","article-title":"Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients","volume":"48","author":"Jorg","year":"2018","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1684\/ejd.2018.3366","article-title":"Immunoglobulin E and bullous pemphigoid","volume":"28","author":"Cozzani","year":"2018","journal-title":"Eur J Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","article-title":"IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review","volume":"310","author":"Saniklidou","year":"2018","journal-title":"Arch Dermatol Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2340\/00015555-2845","article-title":"Biological and clinical response to omalizumab in a patient with bullous pemphigoid","volume":"98","author":"Menzinger","year":"2018","journal-title":"Acta Dermato Venereol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jdermsci.2015.03.002","article-title":"IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?","volume":"78","author":"Ujiie","year":"2015","journal-title":"J Dermatol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"8163803","DOI":"10.1155\/2016\/8163803","article-title":"IgE-Related chronic diseases and anti-IgE-based treatments","volume":"2016","author":"Navines-Ferrer","year":"2016","journal-title":"J Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/cea.12668","article-title":"Comparable actions of omalizumab on mast cells and basophils","volume":"46","author":"Serrano-Candelas","year":"2016","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.4049\/jimmunol.167.3.1290","article-title":"Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI","volume":"167","author":"Borkowski","year":"2001","journal-title":"J Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.7150\/thno.18304","article-title":"Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcepsilonRI-positive cells in the skin","volume":"7","author":"Metz","year":"2017","journal-title":"Theranostics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5021\/ad.2012.24.1.45","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid","volume":"24","author":"Lee","year":"2012","journal-title":"Ann Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.15114","article-title":"Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid","volume":"177","author":"Hashimoto","year":"2017","journal-title":"Br J Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2133.1994.tb02909.x","article-title":"Bullous pemphigoid in a 19\u2013year-old woman. A case with unusual target antigens","volume":"130","author":"Mori","year":"1994","journal-title":"Br J Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0190-9622(87)80227-X","article-title":"Blood eosinophilia as a severity marker for bullous pemphigoid","volume":"16","author":"Bernard","year":"1987","journal-title":"J Am Acad Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0190-9622(83)70073-3","article-title":"Bullous pemphigoid: a cause of peripheral blood eosinophilia","volume":"8","author":"Bushkell","year":"1983","journal-title":"J Am Acad Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/BF01105794","article-title":"High affinity IgE receptor (Fc\u03b5RI) expression on eosinophils infiltrating the lesions and mite patch tested sites in atopic dermatitis","volume":"287","author":"Tanaka","year":"1995","journal-title":"Arch Dermatol Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/all.13131","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid","volume":"72","author":"de Graauw","year":"2017","journal-title":"Allergy."},{"key":"B39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J Allergy Clin Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T03:11:33Z","timestamp":1565838693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2019.01919"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01919","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"article-number":"1919"}}